---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-344608"
form_type: "8-K"
ticker: "BBOT"
cik: "0001869105"
company_name: "BridgeBio Oncology Therapeutics, Inc."
filed_at: "2026-08-11T20:07:16+00:00"
generated_at: "2026-08-11T20:08:28.932369+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# BBOT reports Q2 2026 net loss of $56.5M; cash runway into 2028

## Summary
- Net loss widened to $56.5M in Q2 2026 vs $28.4M in Q2 2025; R&D up to $49.2M from $27.4M.
- G&A rose to $11.0M from $2.7M, reflecting standalone operations, de-SPAC, and one-time severance.
- Cash, equivalents and marketable securities $344.1M as of June 30, 2026; expected runway into 2028.
- Initiated dosing of BBO-11818 + cetuximab and BBO-11818 + BBO-10203 combos; also BBO-8520 + BBO-10203.

## SEC filing metadata
- accession: 0001193125-26-344608
- form_type: 8-K
- ticker: BBOT
- cik: 0001869105
- company_name: BridgeBio Oncology Therapeutics, Inc.
- filed_at: 2026-08-11T20:07:16+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1869105/000119312526344608/0001193125-26-344608-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1869105/000119312526344608/bbot-20260811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-344608
- JSON: https://secwatch.observer/filing/0001193125-26-344608.json
- Plain text: https://secwatch.observer/filing/0001193125-26-344608.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.